α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Alpha Synuclein in Parkinson's Disease Diagnostics

Cells, Free Full-Text

Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)

p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1

Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease: Trends in Endocrinology & Metabolism

Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation

Initiation and propagation of α-synuclein aggregation in the nervous system, Molecular Neurodegeneration

Parkinsons Disease - Neurobiology and Aetiology - Neurotorium

Zeroing in on neurodegenerative α-synuclein

Frontiers Modeling Parkinson's Disease With the Alpha-Synuclein Protein

Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy

Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease

Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

HTRF Phospho-A-Synuclein Ser129 aggregation